Endologix investors should add to positions, says Canaccord Canaccord recommends investors add to positions in Endologix following investor meetings with management. The firm believes top line growth will accelerate in the second half of the year and that Nellix will make it one of the most compelling long-term growth stories in addition to making it an attractive takeover target. Shares are Buy rated with a $17.50 price target.
News For ELGX From The Last 14 Days
Check below for free stories on ELGX the last two weeks.
On The Fly: Analyst Upgrade Summary CBOE Holdings (CBOE) upgraded to Outperform from Market Perform at Raymond James... Silver Bay Realty (SBY) upgraded to Overweight from Neutral at JPMorgan... U.S. Steel (X) upgraded to Outperform from Underperform at Credit Suisse... Endologix (ELGX) upgraded to Buy from Neutral at BTIG... Texas Roadhouse (TXRH) upgraded to Overweight from Equal Weight at Stephens... WPX Energy (WPX) upgraded to Outperform from Sector Perform at Howard Weil... Nomura (NMR) upgraded to Outperform from Neutral at Credit Suisse.